Interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)

被引：0
|
作者：
Weinberg, B. [1 ]
He, A. [1 ]
Tan, B. [2 ]
Turk, A. [3 ]
Noel, M. [1 ]
Marshall, J. [1 ]
Sung, M. [4 ]
Wang, H. [1 ]
Ferguson, C. [1 ]
Swanson, N. [1 ]
Pedersen, K. [2 ]
机构：
[1] Georgetown Univ, Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Indiana Univ Sch Med, Dept Hematol Oncol, Indianapolis, IN USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [21] A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.
    Alese, Olatunji B.
    Shaib, Walid Labib
    Akce, Mehmet
    Wu, Christina
    El-Rayes, Bassel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).
    Dean, Andrew Peter
    Wainberg, Zev A.
    Ramanathan, Ramesh K.
    Boland, Patrick McKay
    Mody, Kabir
    Zhang, Bin
    Belanger, Bruce
    de Jong, Floris A.
    Braun, Stephan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Hubner, R. A.
    Chen, L-T.
    Siveke, J. T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Mamlouk, K.
    Belanger, B.
    de Jong, F.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] Multicenter randomized phase II trial of 5-fluorouracil/leucovorin (5-FU/LV) with or without liposomal irinotecan (nal-IRI) in metastatic biliary tract cancer (BTC) as second-line therapy after progression on gemcitabine plus cisplatin (GemCis): NIFTY trial
    Yoo, C.
    Jeong, J. H.
    Kim, K-P.
    Cheon, J.
    Kim, I.
    Kang, M.
    Ryu, H.
    Kang, B. W.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.
    Ettrich, Thomas Jens
    Berger, Andreas Wolfgang
    Seufferlein, Thomas
    Perkhofer, Lukas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Hubner, Richard
    Mirakhur, Beloo
    de Jong, Floris
    Belanger, Bruce
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin
    Gupta, Medhavi
    Choi, Minsig
    Ramirez, Robert A.
    Attwood, Kristopher
    Mukherjee, Sarbajit
    Iyer, Renuka V.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [28] Long-term survival in patients with pancreatic cancer (PAC) treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV)
    Prager, G.
    Potthoff, K.
    Yoo, C.
    Lonardi, S.
    Hedouin-Biville, F.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S248 - S249
  • [29] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen Li-Tzong
    Andrea, Wang-Gillam
    Shan Yan-Shen
    Teresa, Macarulla
    Jean-Frederic, Blanc
    Richard, Hubner
    Chiu Chang-Fang
    Gilberto, Schwartsmann
    Jens, Siveke
    Marc, Pipas J.
    Bruce, Belanger
    Floris, de Jong
    Khalid, Mamlouk
    Daniel, Von Hoff
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    Li, Chung-Pin
    Wang-Gillam, Andrea
    Bodoky, Gyorgy
    Dean, Andrew Peter
    Shan, Yan-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345